Cassidy, Brown Introduce Bipartisan Bill to Create Emergency Stockpile of Pharmaceutical Ingredients, Shore Up Essential Medicine Supply Chain
WASHINGTON – Today, U.S. Senators Bill Cassidy, M.D. (R-LA) and Sherrod Brown (D-OH) introduced their bipartisan Promoting Readiness and Ensuring Proper Active Pharmaceutical Ingredient Reserves of Essential Medicines (PREPARE) Act of 2021. The PREPARE Act would create an emergency supply of key ingredients used in essential generic medicines and incentivize domestic manufacturing of these ingredients to build a more resilient domestic supply chain.
“COVID reminded us that we are too reliant on foreign countries for generic drugs and pharmaceutical products. This bill brings enough production back to the U.S. so America is better prepared,” said Dr. Cassidy.
“The pandemic has revealed gaping holes and vulnerabilities in our supply chains – perhaps none more critical than our medical supply chain,” said Senator Brown. “This bipartisan legislation will help build emergency capacity for essential medicines here in the U.S. There is no reason we should be relying on countries like China or India for nearly 90 percent of these critical pharmaceutical ingredients, when we have talented scientists and manufacturers right here.”
Right now, the U.S. depends on other countries for a range of pharmaceutical products, including many active pharmaceutical ingredients (APIs) that are essential to create generic prescription drugs. Generic drugs make up 90 percent of all prescriptions filled in the United States, and about 87 percent of API facilities for generic medicines are located overseas.
The PREPARE Act would require the Secretary of Health and Human Services (HHS) to maintain a list of essential generic medicines and build out a domestic supply of the API necessary for those medicines, with a preference for domestic manufacturers and contractors. The legislation will help build emergency capacity for essential API here in the U.S. and support a more resilient domestic supply chain. Specifically, the PREPARE Act would:
- Build on an Executive Order issued in August 2020 to require the HHS Secretary to establish and make public a list of essential generic medicines that are medically necessary to have available at all times;
- Establish a new position within HHS – the Director of the Strategic Active Pharmaceutical Ingredients Reserve – responsible for managing a domestic reserve of essential API;
- Establish a new federal entity to identify, purchase, track, transport, manage, store, and convert an emergency supply of active pharmaceutical ingredients for essential generic medicines; and
- Strengthen U.S. domestic capacity for API production, storage, and conversion into finished dosage form.
The PREPARE Act has been endorsed by organizations representing a variety of roles across the health care continuum, including the Cleveland Clinic, Civica Inc, The Mark Cuban Cost Plus Drug Company, PhLOW, Virginia Commonwealth University and Xellia Pharmaceuticals.
An identical bill will be introduced in the U.S. House of Representatives by Representatives Abigail Spanberger (D-VA-07) and David McKinley (R-WV-01).
“If we’ve learned one thing from the pandemic, it’s that relying on foreign supply chains for vital and lifesaving products is a bad idea. The pharmaceutical industry, and especially active pharmaceutical ingredients, provide a glaring example of our vulnerability,” said Rep. McKinley. “Around 87% of API facilities for generic drugs are located overseas. America needs to develop a resilient domestic supply of API that can avoid shortages of essential medicines during an emergency. Our bipartisan bill would be an important step to building this capacity.”
“Investments in advanced manufacturing techniques of essential medicines can improve our resiliency in the face of public health emergencies, increase American manufacturing capacity, and prevent shortages of lifesaving medicines — but we need to secure the infrastructure necessary to secure, store, and distribute the key ingredients used to make these drugs,” said Rep. Spanberger. “Central Virginia is home to a growing and dynamic biopharmaceutical industry — and this legislation would help secure our domestic supply chains, create new jobs, and keep our nation competitive. I look forward to introducing the House version of this bipartisan legislation soon, and I would like to thank Senators Brown and Cassidy for their leadership on this legislation in the U.S. Senate.”
Next Article Previous Article